Korean J Gastroenterol.  2019 Nov;74(5):298-300. 10.4166/kjg.2019.74.5.298.

Long-term Risk of Malignancy in Branch Duct Intraductal Papillary Mucinous Neoplasms

• Choi EK

• KMID: 2464190
• DOI: http://doi.org/10.4166/kjg.2019.74.5.298

Abstract

No abstract available.

MeSH Terms

Mucins*
Mucins

Reference

1. Pergolini I, Sahora K, Ferrone CR, et al. Long-term risk of pancreatic malignancy in patients with branch duct Intraductal papillary mucinous neoplasm in a referral center. Gastroenterology. 2017; 153:1284–1294.e1.

2. Vege SS, Ziring B, Jain R, Moayyedi P. Clinical Guidelines Committee. American Gastroenterology Association. American Gastroenterological Association institute guideline on the diagnosis and management of asymptomatic neoplastic pancreatic cysts. Gastroenterology. 2015; 148:819–822.

3. Oyama H, Tada M, Takagi K. Long-term risk of malignancy in branch duct intraductal papillary mucinous neoplasms. Gastroenterology. 2019; 08. 29. [Epub ahead of print].

4. Moris M, Bridges MD, Pooley RA, et al. Association between advances in high-resolution cross-section imaging technologies and increase in prevalence of pancreatic cysts from 2005 to 2014. Clin Gastroenterol Hepatol. 2016; 14:585–593.e3.

5. Tanaka M, Fernández-Del Castillo C, Kamisawa T, et al. Revisions of international consensus Fukuoka guidelines for the management of IPMN of the pancreas. Pancreatology. 2017; 17:738–753.

6. Tanaka M, Fernández-del Castillo C, Adsay V, et al. International consensus guidelines 2012 for the management of IPMN and MCN of the pancreas. Pancreatology. 2012; 12:183–197.

7. Maguchi H, Tanno S, Mizuno N, et al. Natural history of branch duct intraductal papillary mucinous neoplasms of the pancreas: a multicenter study in Japan. Pancreas. 2011; 40:364–370.

8. Yamaguchi K, Kanemitsu S, Hatori T, et al. Pancreatic ductal adenocarcinoma derived from IPMN and pancreatic ductal adenocarcinoma concomitant with IPMN. Pancreas. 2011; 40:571–580.

9. Bailey P, Chang DK, Nones K, et al. Genomic analyses identify molecular subtypes of pancreatic cancer. Nature. 2016; 531:47–52.

10. Molin MD, Matthaei H, Wu J, et al. Clinicopathological correlates of activating GNAS mutations in intraductal papillary mucinous neoplasm (IPMN) of the pancreas. Ann Surg Oncol. 2013; 20:3802–3808.

11. Omori Y, Ono Y, Tanino M, et al. Pathways of progression from intraductal papillary mucinous neoplasm to pancreatic ductal adenocarcinoma based on molecular features. Gastroenterology. 2019; 156:647–661.e2.

12. Malleo G, Marchegiani G, Borin A, et al. Observational study of the incidence of pancreatic and extrapancreatic malignancies during surveillance of patients with branch-duct intraductal papillary mucinous neoplasm. Ann Surg. 2015; 261:984–990.

13. Kwong WT, Hunt GC, Fehmi SM, et al. Low rates of malignancy and mortality in asymptomatic patients with suspected neoplastic pancreatic cysts beyond 5 years of surveillance. Clin Gastroenterol Hepatol. 2016; 14:865–871.

14. Maimone S, Agrawal D, Pollack MJ, et al. Variability in measurements of pancreatic cyst size among EUS, CT, and magnetic resonance imaging modalities. Gastrointest Endosc. 2010; 71:945–950.